Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Phytoconstituents of Artemisia Annua as potential inhibitors of SARS CoV2 main protease: an in silico study

Irfan et al., BMC Infectious Diseases, doi:10.1186/s12879-024-09387-w
May 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Quercetin for COVID-19
24th treatment shown to reduce risk in July 2021, now with p = 0.002 from 12 studies.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
In Silico study showing that quercetin binds strongly to the SARS-CoV-2 main protease (Mpro) and may be a potential inhibitor of viral replication. Authors screened 25 compounds from Artemisia annua and found that quercetin had one of the best docking scores against Mpro, forming two hydrogen bonds and several hydrophobic interactions with key residues in the protein's active site. Quercetin was identified as one of the top hits along with rutin, casticin, chrysoplenetin, apigenin, artemetin, artesunate, scopolin and sitogluside. Chrysoplenetin was the most promising lead compound after ADMET analysis.
73 preclinical studies support the efficacy of quercetin for COVID-19:
In Silico studies predict inhibition of SARS-CoV-2, or minimization of side effects, with quercetin or metabolites via binding to the spikeA,3,9,10,22,24,25,30,38,39,41,42,62-64, MproB,3,7,9,11,13,15,17,18,20,23,24,30,34,36-38,42,43,45,63-65, RNA-dependent RNA polymeraseC,1,3,9,32,64, PLproD,3,37,45, ACE2E,22,23,28,37,41,63, TMPRSS2F,22, nucleocapsidG,3, helicaseH,3,29,34, endoribonucleaseI,39, NSP16/10J,6, cathepsin LK,26, Wnt-3L,22, FZDM,22, LRP6N,22, ezrinO,40, ADRPP,38, NRP1Q,41, EP300R,16, PTGS2S,23, HSP90AA1T,16,23, matrix metalloproteinase 9U,31, IL-6V,21,35, IL-10W,21, VEGFAX,35, and RELAY,35 proteins. In Vitro studies demonstrate inhibition of the MproB,15,46,51,59 protein, and inhibition of spike-ACE2 interactionZ,47. In Vitro studies demonstrate efficacy in Calu-3AA,50, A549AB,21, HEK293-ACE2+AC,58, Huh-7AD,25, Caco-2AE,49, Vero E6AF,19,42,49, mTECAG,52, and RAW264.7AH,52 cells. Animal studies demonstrate efficacy in K18-hACE2 miceAI,55, db/db miceAJ,52,61, BALB/c miceAK,60, and rats66. Quercetin reduced proinflammatory cytokines and protected lung and kidney tissue against LPS-induced damage in mice60, inhibits LPS-induced cytokine storm by modulating key inflammatory and antioxidant pathways in macrophages5, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity54.
a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.
b. The main protease or Mpro, also known as 3CLpro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting Mpro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.
c. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.
d. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.
e. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.
f. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.
g. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.
h. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.
i. The endoribonuclease, also known as NendoU or nsp15, cleaves specific sequences in viral RNA which may help the virus evade detection by the host immune system. Inhibition may hinder the virus's ability to mask itself from the immune system, facilitating a stronger immune response.
j. The NSP16/10 complex consists of non-structural proteins 16 and 10, forming a 2'-O-methyltransferase that modifies the viral RNA cap structure. This modification helps the virus evade host immune detection by mimicking host mRNA, making NSP16/10 a promising antiviral target.
k. Cathepsin L is a host lysosomal cysteine protease that can prime the spike protein through an alternative pathway when TMPRSS2 is unavailable. Dual targeting of cathepsin L and TMPRSS2 may maximize disruption of alternative pathways for virus entry.
l. Wingless-related integration site (Wnt) ligand 3 is a host signaling molecule that activates the Wnt signaling pathway, which is important in development, cell growth, and tissue repair. Some studies suggest that SARS-CoV-2 infection may interfere with the Wnt signaling pathway, and that Wnt3a is involved in SARS-CoV-2 entry.
m. The frizzled (FZD) receptor is a host transmembrane receptor that binds Wnt ligands, initiating the Wnt signaling cascade. FZD serves as a co-receptor, along with ACE2, in some proposed mechanisms of SARS-CoV-2 infection. The virus may take advantage of this pathway as an alternative entry route.
n. Low-density lipoprotein receptor-related protein 6 is a cell surface co-receptor essential for Wnt signaling. LRP6 acts in tandem with FZD for signal transduction and has been discussed as a potential co-receptor for SARS-CoV-2 entry.
o. The ezrin protein links the cell membrane to the cytoskeleton (the cell's internal support structure) and plays a role in cell shape, movement, adhesion, and signaling. Drugs that occupy the same spot on ezrin where the viral spike protein would bind may hindering viral attachment, and drug binding could further stabilize ezrin, strengthening its potential natural capacity to impede viral fusion and entry.
p. The Adipocyte Differentiation-Related Protein (ADRP, also known as Perilipin 2 or PLIN2) is a lipid droplet protein regulating the storage and breakdown of fats in cells. SARS-CoV-2 may hijack the lipid handling machinery of host cells and ADRP may play a role in this process. Disrupting ADRP's interaction with the virus may hinder the virus's ability to use lipids for replication and assembly.
q. Neuropilin-1 (NRP1) is a cell surface receptor with roles in blood vessel development, nerve cell guidance, and immune responses. NRP1 may function as a co-receptor for SARS-CoV-2, facilitating viral entry into cells. Blocking NRP1 may disrupt an alternative route of viral entry.
r. EP300 (E1A Binding Protein P300) is a transcriptional coactivator involved in several cellular processes, including growth, differentiation, and apoptosis, through its acetyltransferase activity that modifies histones and non-histone proteins. EP300 facilitates viral entry into cells and upregulates inflammatory cytokine production.
s. Prostaglandin G/H synthase 2 (PTGS2, also known as COX-2) is an enzyme crucial for the production of inflammatory molecules called prostaglandins. PTGS2 plays a role in the inflammatory response that can become severe in COVID-19 and inhibitors (like some NSAIDs) may have benefits in dampening harmful inflammation, but note that prostaglandins have diverse physiological functions.
t. Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1) is a chaperone protein that helps other proteins fold correctly and maintains their stability. HSP90AA1 plays roles in cell signaling, survival, and immune responses. HSP90AA1 may interact with numerous viral proteins, but note that it has diverse physiological functions.
u. Matrix metalloproteinase 9 (MMP9), also called gelatinase B, is a zinc-dependent enzyme that breaks down collagen and other components of the extracellular matrix. MMP9 levels increase in severe COVID-19. Overactive MMP9 can damage lung tissue and worsen inflammation. Inhibition of MMP9 may prevent excessive tissue damage and help regulate the inflammatory response.
v. The interleukin-6 (IL-6) pro-inflammatory cytokine (signaling molecule) has a complex role in the immune response and may trigger and perpetuate inflammation. Elevated IL-6 levels are associated with severe COVID-19 cases and cytokine storm. Anti-IL-6 therapies may be beneficial in reducing excessive inflammation in severe COVID-19 cases.
w. The interleukin-10 (IL-10) anti-inflammatory cytokine helps regulate and dampen immune responses, preventing excessive inflammation. IL-10 levels can also be elevated in severe COVID-19. IL-10 could either help control harmful inflammation or potentially contribute to immune suppression.
x. Vascular Endothelial Growth Factor A (VEGFA) promotes the growth of new blood vessels (angiogenesis) and has roles in inflammation and immune responses. VEGFA may contribute to blood vessel leakiness and excessive inflammation associated with severe COVID-19.
y. RELA is a transcription factor subunit of NF-kB and is a key regulator of inflammation, driving pro-inflammatory gene expression. SARS-CoV-2 may hijack and modulate NF-kB pathways.
z. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.
aa. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.
ab. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.
ac. HEK293-ACE2+ is a human embryonic kidney cell line engineered for high ACE2 expression and SARS-CoV-2 susceptibility.
ad. Huh-7 cells were derived from a liver tumor (hepatoma).
ae. Caco-2 cells come from a colorectal adenocarcinoma (cancer). They are valued for their ability to form a polarized cell layer with properties similar to the intestinal lining.
af. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.
ag. mTEC is a mouse tubular epithelial cell line.
ah. RAW264.7 is a mouse macrophage cell line.
ai. A mouse model expressing the human ACE2 receptor under the control of the K18 promoter.
aj. A mouse model of obesity and severe insulin resistance leading to type 2 diabetes due to a mutation in the leptin receptor gene that impairs satiety signaling.
ak. A mouse model commonly used in infectious disease and cancer research due to higher immune response and susceptibility to infection.
Irfan et al., 15 May 2024, peer-reviewed, 7 authors. Contact: dr.erum@cust.edu.pk, abdi@pgu.ac.ir, yasir_waheed_199@hotmail.com.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperQuercetinAll
Phytoconstituents of Artemisia Annua as potential inhibitors of SARS CoV2 main protease: an in silico study
Eraj Irfan, Erum Dilshad, Faisal Ahmad, Fahad Nasser Almajhdi, Tajamul Hussain, Gholamreza Abdi, Yasir Waheed
BMC Infectious Diseases, doi:10.1186/s12879-024-09387-w
Background In November 2019, the world faced a pandemic called SARS-CoV-2, which became a major threat to humans and continues to be. To overcome this, many plants were explored to find a cure. Methods Therefore, this research was planned to screen out the active constituents from Artemisia annua that can work against the viral main protease Mpro as this non-structural protein is responsible for the cleavage of replicating enzymes of the virus. Twenty-five biocompounds belonging to different classes namely alpha-pinene, beta-pinene, carvone, myrtenol, quinic acid, caffeic acid, quercetin, rutin, apigenin, chrysoplenetin, arteannunin b, artemisinin, scopoletin, scoparone, artemisinic acid, deoxyartemisnin, artemetin, casticin, sitogluside, beta-sitosterol, dihydroartemisinin, scopolin, artemether, artemotil, artesunate were selected. Virtual screening of these ligands was carried out against drug target Mpro by CB dock. Results Quercetin, rutin, casticin, chrysoplenetin, apigenin, artemetin, artesunate, sopolin and sito-gluside were found as hit compounds. Further, ADMET screening was conducted which represented Chrysoplenetin as a lead compound. Azithromycin was used as a standard drug. The interactions were studied by PyMol and visualized in LigPlot. Furthermore, the RMSD graph shows fluctuations at various points at the start of simulation in Top1 (Azithromycin) complex system due to structural changes in the helix-coil-helix and beta-turn-beta changes at specific points resulting in increased RMSD with a time frame of 50 ns. But this change remains stable after the extension of simulation time intervals till 100 ns. On other side, the Top2 complex system remains highly stable throughout the time scale. No such structural dynamics were observed bu the ligand attached to the active site residues binds strongly. Conclusion This study facilitates researchers to develop and discover more effective and specific therapeutic agents against SARS-CoV-2 and other viral infections. Finally, chrysoplenetin was identified as a more potent drug candidate to act against the viral main protease, which in the future can be helpful.
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s12879-024-09387-w. Supplementary Materials 1: Table S1 . Applicability of Lipinski rule. Table S2 Selected ligands with structural information. Table S3 Absorption properties of the ligands and standard drug. Table S4 Distribution properties of the ligands and standard drug. Table S5 Lipinski's Rule Comparison. Authors' contributions Eraj Irfan: Concept, methodology, formal analysis, data curation, manuscript writing, final approval. Erum Dilshad: Concept, methodology, formal analysis, data curation, manuscript editing, Supervision, final approval. Faisal Ahmad: methodology, formal analysis, data curation, manuscript writing, manuscript editing, final approval. Fahad N Almajhdi: methodology, formal analysis, data curation, manuscript editing, Supervision, resources, final approval. Tajamul Hussain: methodology, formal analysis, data curation, manuscript editing, resources, final approval. Gholamreza Abdi: methodology, formal analysis, data curation, manuscript editing, resources, final approval. Yasir Waheed: Concept, methodology, formal analysis, data curation, manuscript editing, Supervision, resources, final approval. Declarations Ethics approval and consent to participate It's a computational work, ethical approval not required. Consent for publication Not applicable. Competing interests The authors declare no competing interests. ..
References
Abdusalam, Murugaiyah, Identification of potential inhibitors of 3CL protease of SARS-CoV-2 from ZINC database by molecular dockingbased virtual screening, Front Mol Biosci
Ahmad, Abbasi, Shahid, Gul, Abbasi, Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment, J Biomol Struct Dyn
Anand, Balamuralikrishnan, Kaviya, Bharathi, Parithathvi et al., Medicinal plants, phytochemicals, and herbs to combat viral pathogens including SARS-CoV-2, Molecules
Anand, Ziebuhr, Wadhwani, Mesters, Hilgenfeld, Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs, Science
Benhander, Abdusalam, Identification of potential inhibitors of SARS-CoV-2 main protease from Allium roseum L. Molecular docking study, Chem Afr
Biovia, Discovery studio visualizer
Boni, Lemey, Jiang, Lam, Perry et al., Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic, Nat Microbiol
Burley, Berman, Kleywegt, Markley, Nakamura et al., Protein Data Bank (PDB): the single global macromolecular structure archive, Methods Mol Biol
Case, Betz, Cerutti, Cheatham, Darden et al., Amber 16, doi:10.13140/rg.2.2.27958.70729
Cavarzeljkovic, Maksimović, Vidic, Paric, Chemical composition and antioxidant and antimicrobial activity of essential oil of Artemisia annua L. from Bosnia, Industr Crops Prod
Cheng, Li, Liu, Tang, In silico ADMET prediction: recent advances, current challenges and future trends, Curr Top Med Chem
Cousins, Computer review of ChemDraw ultra 12
Daina, Michielin, Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci Rep
Desmond, Schrödinger
Drosten, Günther, Preiser, Van Der Werf, Brodt et al., Identification of a novel coronavirus in patients with severe acute respiratory syndrome, N Engl J Med
Drożdżal, Rosik, Lechowicz, Machaj, Kotfis et al., FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy, Drug Resist Updat
Ferreira, Santos, Oliva, Andricopulo, Molecular docking and structure-based drug design strategies, Molecules
Forni, Facchiano, Bartoli, Pieretti, Facchiano et al., Beneficial role of phytochemicals on oxidative stress and age-related diseases, Biomed Res Int
Hildebrand, Rose, Tiemann, Bringing molecular dynamics simulation data into view, Trends Biochem Sci
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Jia, Li, Hao, Yang, A drug-likeness toolbox facilitates ADMET study in drug discovery, Drug Discov Today
Jin, Du, Xu, Deng, Liu et al., Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors, Nature
Jn, Fa, Aa, Rh, Am et al., Antileishmanial activity of novel indolyl-coumarin hybrids: design, synthesis, biological evaluation, molecular docking study and in silico ADME prediction, Bioorg Med Chem Lett
Karplus, Kuriyan, Molecular dynamics and protein function, Proc Natl Acad Sci
Khurshid, Determination of Potential Antioxidants of Artemisia annua by Computational Approaches
Kumar, Tan, Wang, Lin, Liang, Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors, Bioorg Med Chem
Li, Dong, Ma, Wu, Yan et al., Antifungal coumarins and lignans from Artemisia annua, Fitoterapia
Lipinski, Lead-and drug-like compounds: the rule-of-five revolution, Drug Discov Today Technol
Liu, Grimm, Dai, Hou, Xiao et al., CB-Dock: a web server for cavity detection-guided protein-ligand blind docking, Acta Pharmacol Sin
Liu, Health-promoting components of fruits and vegetables in the diet, Adv Nutr
Machhi, Herskovitz, Senan, Dutta, Nath et al., The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections, J Neuroimmune Pharmacol
Malaterre, Rakoto, Marodon, Bedoui, Nakab et al., Artemisia annua, a traditional plant brought to light, Int J Mol Sci
Mgltools, Get the software safely and easily, Software Informer
Ntie-Kang, An in silico evaluation of the ADMET profile of the Strep-tomeDB database, Springerplus
O'boyle, Banck, James, Morley, Vandermeersch et al., Open babel: an open chemical toolbox, J Cheminform
Pagadala, Syed, Tuszynski, Software for molecular docking: a review, Biophys Rev
Pires, Blundell, Ascher, pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures, J Med Chem
Protparam, ExPASy-ProtParam tool
Rasheed, Iqbal, Saddick, Ali, Khan et al., Identification of lead compounds against Scm (fms10) in Enterococcus faecium using computer aided drug designing, Life
Shereen, Khan, Kazmi, Bashir, Siddique, COVID-19 infection: origin, transmission, and characteristics of human coronaviruses, J Adv Res
Taofeek, Molecular Docking and Admet Analyses of Photochemicals from Nigella sativa (blackseed), Trigonella foenum-graecum (Fenugreek) and Anona muricata (Soursop) on SARS-CoV-2 Target, ScienceOpen Preprints, doi:10.14293/S2199-1006.1.SOR-.PPKNVFY.v1
Ul Qamar, Alqahtani, Alamri, Chen, Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants, J Pharm Anal
Vallès, Garcia, Hidalgo, Martín, Pellicer et al., Biology, genome evolution, biotechnological issues and research including applied perspectives in Artemisia (Asteraceae), Adv Bot Res
Vijayakumar, Janani, Kannappan, Renganathan, Al-Ghamdi et al., In silico identification of potential inhibitors against main protease of SARS-CoV-2 6LU7 from Andrographis panniculata via molecular docking, binding energy calculations and molecular dynamics simulation studies, Saudi J Biol Sci
Wallace, Laskowski, Thornton, LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions, Protein Eng Des Sel
Wang, Horby, Hayden, Gao, A novel coronavirus outbreak of global health concern, The Lancet
Wilcox, Artemisia species: from traditional medicines to modern antimalarials-and back again, J Altern Complement Med
Yuriev, Holien, Ramsland, Improvements, trends, and new ideas in molecular docking: 2012-2013 in review, J Mol Recognit
Yuriev, Ramsland, Latest developments in molecular docking: 2010-2011 in review, J Mol Recognit
Zhang, Lin, Sun, Curth, Drosten et al., Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved $\alpha$-ketoamide inhibitors, Science
Ziebuhr, Snijder, Gorbalenya, Virus-encoded proteinases and proteolytic processing in the Nidovirales, J Gen Virol
{ 'indexed': {'date-parts': [[2024, 5, 16]], 'date-time': '2024-05-16T00:37:56Z', 'timestamp': 1715819876956}, 'reference-count': 52, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2024, 5, 15]], 'date-time': '2024-05-15T00:00:00Z', 'timestamp': 1715731200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2024, 5, 15]], 'date-time': '2024-05-15T00:00:00Z', 'timestamp': 1715731200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>In November 2019, the world faced a pandemic called SARS-CoV-2, which ' 'became a major threat to humans and continues to be. To overcome this, many plants were ' 'explored to find a cure.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>Therefore, this research was planned to screen out the active ' 'constituents from <jats:italic>Artemisia annua</jats:italic> that can work against the viral ' 'main protease Mpro as this non-structural protein is responsible for the cleavage of ' 'replicating enzymes of the virus. Twenty-five biocompounds belonging to different classes ' 'namely alpha-pinene, beta-pinene, carvone, myrtenol, quinic acid, caffeic acid, quercetin, ' 'rutin, apigenin, chrysoplenetin, arteannunin b, artemisinin, scopoletin, scoparone, ' 'artemisinic acid, deoxyartemisnin, artemetin, casticin, sitogluside, beta-sitosterol, ' 'dihydroartemisinin, scopolin, artemether, artemotil, artesunate were selected. Virtual ' 'screening of these ligands was carried out against drug target Mpro by CB dock.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Quercetin, rutin, casticin, chrysoplenetin, apigenin, artemetin, ' 'artesunate, sopolin and sito-gluside were found as hit compounds. Further, ADMET screening ' 'was conducted which represented Chrysoplenetin as a lead compound. Azithromycin was used as a ' 'standard drug. The interactions were studied by PyMol and visualized in LigPlot. Furthermore, ' 'the RMSD graph shows fluctuations at various points at the start of simulation in Top1 ' '(Azithromycin) complex system due to structural changes in the helix-coil-helix and ' 'beta-turn-beta changes at specific points resulting in increased RMSD with a time frame of ' '50\xa0ns. But this change remains stable after the extension of simulation time intervals ' 'till 100\xa0ns. On other side, the Top2 complex system remains highly stable throughout the ' 'time scale. No such structural dynamics were observed bu the ligand attached to the active ' 'site residues binds strongly.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>This study facilitates researchers to develop and discover more ' 'effective and specific therapeutic agents against SARS-CoV-2 and other viral infections. ' 'Finally, chrysoplenetin was identified as a more potent drug candidate to act against the ' 'viral main protease, which in the future can be helpful.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1186/s12879-024-09387-w', 'type': 'journal-article', 'created': {'date-parts': [[2024, 5, 15]], 'date-time': '2024-05-15T10:02:12Z', 'timestamp': 1715767332000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Phytoconstituents of Artemisia Annua as potential inhibitors of SARS CoV2 main protease: an in ' 'silico study', 'prefix': '10.1186', 'volume': '24', 'author': [ {'given': 'Eraj', 'family': 'Irfan', 'sequence': 'first', 'affiliation': []}, {'given': 'Erum', 'family': 'Dilshad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Faisal', 'family': 'Ahmad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fahad Nasser', 'family': 'Almajhdi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tajamul', 'family': 'Hussain', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gholamreza', 'family': 'Abdi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yasir', 'family': 'Waheed', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2024, 5, 15]]}, 'reference': [ { 'key': '9387_CR1', 'doi-asserted-by': 'publisher', 'first-page': '470', 'DOI': '10.1016/S0140-6736(20)30185-9', 'volume': '395', 'author': 'C Wang', 'year': '2020', 'unstructured': 'Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of ' 'global health concern. The Lancet. 2020;395:470.', 'journal-title': 'The Lancet'}, { 'key': '9387_CR2', 'doi-asserted-by': 'publisher', 'first-page': '359', 'DOI': '10.1007/s11481-020-09944-5', 'volume': '15', 'author': 'J Machhi', 'year': '2020', 'unstructured': 'Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al. ' 'The natural history, pathobiology, and clinical manifestations of ' 'SARS-CoV-2 infections. J Neuroimmune Pharmacol. 2020;15:359–86.', 'journal-title': 'J Neuroimmune Pharmacol'}, { 'key': '9387_CR3', 'doi-asserted-by': 'publisher', 'first-page': '91', 'DOI': '10.1016/j.jare.2020.03.005', 'volume': '24', 'author': 'MA Shereen', 'year': '2020', 'unstructured': 'Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: ' 'origin, transmission, and characteristics of human coronaviruses. J Adv ' 'Res. 2020;24:91–8.', 'journal-title': 'J Adv Res'}, { 'key': '9387_CR4', 'doi-asserted-by': 'publisher', 'first-page': '497', 'DOI': '10.1016/S0140-6736(20)30183-5', 'volume': '395', 'author': 'C Huang', 'year': '2020', 'unstructured': 'Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of ' 'patients infected with 2019 novel coronavirus in Wuhan China. Lancet. ' '2020;395:497. https://doi.org/10.1016/S0140-6736(20)30183-5.', 'journal-title': 'Lancet'}, { 'issue': 'Pt 4', 'key': '9387_CR5', 'doi-asserted-by': 'publisher', 'first-page': '853', 'DOI': '10.1099/0022-1317-81-4-853', 'volume': '81', 'author': 'J Ziebuhr', 'year': '2000', 'unstructured': 'Ziebuhr J, Snijder EJ, Gorbalenya AE. Virus-encoded proteinases and ' 'proteolytic processing in the Nidovirales. J Gen Virol. 2000;81(Pt ' '4):853–79.', 'journal-title': 'J Gen Virol'}, { 'key': '9387_CR6', 'doi-asserted-by': 'publisher', 'first-page': '289', 'DOI': '10.1038/s41586-020-2223-y', 'volume': '582', 'author': 'Z Jin', 'year': '2020', 'unstructured': 'Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from ' 'SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–93.', 'journal-title': 'Nature'}, { 'key': '9387_CR7', 'doi-asserted-by': 'publisher', 'first-page': '409', 'DOI': '10.1126/science.abb3405', 'volume': '368', 'author': 'L Zhang', 'year': '2020', 'unstructured': 'Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal ' 'structure of SARS-CoV-2 main protease provides a basis for design of ' 'improved $\\alpha$-ketoamide inhibitors. Science. 2020;368:409–12.', 'journal-title': 'Science'}, { 'key': '9387_CR8', 'doi-asserted-by': 'publisher', 'first-page': '3035', 'DOI': '10.1016/j.bmc.2016.05.013', 'volume': '24', 'author': 'V Kumar', 'year': '2016', 'unstructured': 'Kumar V, Tan K-P, Wang Y-M, Lin S-W, Liang P-H. Identification, ' 'synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease ' 'inhibitors. Bioorg Med Chem. 2016;24:3035–42.', 'journal-title': 'Bioorg Med Chem'}, { 'key': '9387_CR9', 'doi-asserted-by': 'publisher', 'first-page': '1967', 'DOI': '10.1056/NEJMoa030747', 'volume': '348', 'author': 'C Drosten', 'year': '2003', 'unstructured': 'Drosten C, Günther S, Preiser W, van der Werf S, Brodt H-R, Becker S, et ' 'al. Identification of a novel coronavirus in patients with severe acute ' 'respiratory syndrome. N Engl J Med. 2003;348:1967–76.', 'journal-title': 'N Engl J Med'}, { 'key': '9387_CR10', 'doi-asserted-by': 'publisher', 'first-page': '1408', 'DOI': '10.1038/s41564-020-0771-4', 'volume': '5', 'author': 'MF Boni', 'year': '2020', 'unstructured': 'Boni MF, Lemey P, Jiang X, Lam TT-Y, Perry BW, Castoe TA, et al. ' 'Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible ' 'for the COVID-19 pandemic. Nat Microbiol. 2020;5:1408–17.', 'journal-title': 'Nat Microbiol.'}, { 'key': '9387_CR11', 'unstructured': 'Understand your COVID-19 risk status and treatment options. Ada. ' 'https://ada.com/covid/antiviral-treatment-criteria-questionnaire/. ' 'Accessed 9 Aug 2023.'}, { 'key': '9387_CR12', 'doi-asserted-by': 'publisher', 'first-page': '100719', 'DOI': '10.1016/j.drup.2020.100719', 'volume': '53', 'author': 'S Drożdżal', 'year': '2020', 'unstructured': 'Drożdżal S, Rosik J, Lechowicz K, Machaj F, Kotfis K, Ghavami S, et al. ' 'FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 ' '(COVID-19) therapy. Drug Resist Updat. 2020;53:100719.', 'journal-title': 'Drug Resist Updat'}, { 'key': '9387_CR13', 'doi-asserted-by': 'publisher', 'first-page': '479', 'DOI': '10.1016/j.indcrop.2011.07.024', 'volume': '37', 'author': 'S CavarZeljkovic', 'year': '2012', 'unstructured': 'CavarZeljkovic S, Maksimović M, Vidic D, Paric A. Chemical composition ' 'and antioxidant and antimicrobial activity of essential oil of Artemisia ' 'annua L. from Bosnia. Industr Crops Prod. 2012;37:479–85.', 'journal-title': 'Industr Crops Prod'}, { 'key': '9387_CR14', 'doi-asserted-by': 'publisher', 'first-page': '323', 'DOI': '10.1016/j.fitote.2019.02.022', 'volume': '134', 'author': 'K-M Li', 'year': '2019', 'unstructured': 'Li K-M, Dong X, Ma Y-N, Wu Z-H, Yan Y-M, Cheng Y-X. Antifungal coumarins ' 'and lignans from Artemisia annua. Fitoterapia. 2019;134:323–8.', 'journal-title': 'Fitoterapia'}, { 'key': '9387_CR15', 'doi-asserted-by': 'publisher', 'first-page': '1775', 'DOI': '10.3390/molecules26061775', 'volume': '26', 'author': 'AV Anand', 'year': '2021', 'unstructured': 'Anand AV, Balamuralikrishnan B, Kaviya M, Bharathi K, Parithathvi A, ' 'Arun M, et al. Medicinal plants, phytochemicals, and herbs to combat ' 'viral pathogens including SARS-CoV-2. Molecules. 2021;26:1775.', 'journal-title': 'Molecules'}, { 'key': '9387_CR16', 'doi-asserted-by': 'publisher', 'first-page': '384S', 'DOI': '10.3945/an.112.003517', 'volume': '4', 'author': 'RH Liu', 'year': '2013', 'unstructured': 'Liu RH. Health-promoting components of fruits and vegetables in the ' 'diet. Adv Nutr. 2013;4:384S-392S.', 'journal-title': 'Adv Nutr'}, { 'key': '9387_CR17', 'doi-asserted-by': 'publisher', 'first-page': 'e8748253', 'DOI': '10.1155/2019/8748253', 'volume': '2019', 'author': 'C Forni', 'year': '2019', 'unstructured': 'Forni C, Facchiano F, Bartoli M, Pieretti S, Facchiano A, D’Arcangelo D, ' 'et al. Beneficial role of phytochemicals on oxidative stress and ' 'age-related diseases. Biomed Res Int. 2019;2019:e8748253.', 'journal-title': 'Biomed Res Int'}, { 'issue': '12', 'key': '9387_CR18', 'doi-asserted-by': 'publisher', 'first-page': '4225', 'DOI': '10.1080/07391102.2020.1775129', 'volume': '39', 'author': 'S Ahmad', 'year': '2021', 'unstructured': 'Ahmad S, Abbasi HW, Shahid S, Gul S, Abbasi SW. Molecular docking, ' 'simulation and MM-PBSA studies of nigella sativa compounds: a ' 'computational quest to identify potential natural antiviral for COVID-19 ' 'treatment. J Biomol Struct Dyn. 2021;39(12):4225–33.', 'journal-title': 'J Biomol Struct Dyn.'}, { 'key': '9387_CR19', 'doi-asserted-by': 'publisher', 'first-page': '215', 'DOI': '10.1002/jmr.2266', 'volume': '26', 'author': 'E Yuriev', 'year': '2013', 'unstructured': 'Yuriev E, Ramsland PA. Latest developments in molecular docking: ' '2010–2011 in review. J Mol Recognit. 2013;26:215–39.', 'journal-title': 'J Mol Recognit'}, { 'key': '9387_CR20', 'unstructured': 'Desmond | Schrödinger. https://www.schrodinger.com/products/desmond. ' 'Accessed 2 Aug 2023.'}, { 'key': '9387_CR21', 'unstructured': 'ProtParam E. ExPASy-ProtParam tool. 2017. Available at ' 'https://web.expasy.org/protparam/. Accessed 04 Aug 2023.'}, { 'key': '9387_CR22', 'doi-asserted-by': 'crossref', 'unstructured': 'Cousins KR. Computer review of ChemDraw ultra 12.0. ACS Publications; ' '2011;133(21):8388.', 'DOI': '10.1021/ja204075s'}, { 'key': '9387_CR23', 'doi-asserted-by': 'publisher', 'first-page': '42717', 'DOI': '10.1038/srep42717', 'volume': '7', 'author': 'A Daina', 'year': '2017', 'unstructured': 'Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate ' 'pharmacokinetics, drug-likeness and medicinal chemistry friendliness of ' 'small molecules. Sci Rep. 2017;7:42717.', 'journal-title': 'Sci Rep'}, { 'key': '9387_CR24', 'doi-asserted-by': 'publisher', 'first-page': '337', 'DOI': '10.1016/j.ddtec.2004.11.007', 'volume': '1', 'author': 'CA Lipinski', 'year': '2004', 'unstructured': 'Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. ' 'Drug Discov Today Technol. 2004;1:337–41.', 'journal-title': 'Drug Discov Today Technol'}, { 'key': '9387_CR25', 'doi-asserted-by': 'publisher', 'first-page': '138', 'DOI': '10.1038/s41401-019-0228-6', 'volume': '41', 'author': 'Y Liu', 'year': '2020', 'unstructured': 'Liu Y, Grimm M, Dai W, Hou M, Xiao Z-X, Cao Y. CB-Dock: a web server for ' 'cavity detection-guided protein–ligand blind docking. Acta Pharmacol ' 'Sin. 2020;41:138–44.', 'journal-title': 'Acta Pharmacol Sin'}, { 'issue': '1', 'key': '9387_CR26', 'doi-asserted-by': 'publisher', 'first-page': '248', 'DOI': '10.1016/j.drudis.2019.10.014', 'volume': '25', 'author': 'C-Y Jia', 'year': '2020', 'unstructured': 'Jia C-Y, Li J-Y, Hao G-F, Yang G-F. A drug-likeness toolbox facilitates ' 'ADMET study in drug discovery. Drug Discov Today. 2020;25(1):248–58.', 'journal-title': 'Drug Discov Today.'}, { 'key': '9387_CR27', 'doi-asserted-by': 'publisher', 'first-page': '13384', 'DOI': '10.3390/molecules200713384', 'volume': '20', 'author': 'LG Ferreira', 'year': '2015', 'unstructured': 'Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking ' 'and structure-based drug design strategies. Molecules. ' '2015;20:13384–421.', 'journal-title': 'Molecules'}, { 'key': '9387_CR28', 'doi-asserted-by': 'publisher', 'unstructured': 'Case DA, Betz RM, D.S. Cerutti, Cheatham T, Darden T, Duke RE, et al. ' 'Amber 16, University of California, San Francisco. University of ' 'California, San Francisco. 2016. ' 'https://doi.org/10.13140/rg.2.2.27958.70729.', 'DOI': '10.13140/rg.2.2.27958.70729'}, { 'key': '9387_CR29', 'doi-asserted-by': 'publisher', 'first-page': '902', 'DOI': '10.1016/j.tibs.2019.06.004', 'volume': '44', 'author': 'PW Hildebrand', 'year': '2019', 'unstructured': 'Hildebrand PW, Rose AS, Tiemann JKS. Bringing molecular dynamics ' 'simulation data into view. Trends Biochem Sci. 2019;44:902–13.', 'journal-title': 'Trends Biochem Sci'}, { 'key': '9387_CR30', 'first-page': '77', 'volume': '11', 'author': 'MA Rasheed', 'year': '2021', 'unstructured': 'Rasheed MA, Iqbal MN, Saddick S, Ali I, Khan FS, Kanwal S, et al. ' 'Identification of lead compounds against Scm (fms10) in Enterococcus ' 'faecium using computer aided drug designing. Life (Basel). 2021;11:77.', 'journal-title': 'Life (Basel)'}, { 'key': '9387_CR31', 'doi-asserted-by': 'publisher', 'first-page': '627', 'DOI': '10.1007/978-1-4939-7000-1_26', 'volume': '1607', 'author': 'SK Burley', 'year': '2017', 'unstructured': 'Burley SK, Berman HM, Kleywegt GJ, Markley JL, Nakamura H, Velankar S. ' 'Protein Data Bank (PDB): the single global macromolecular structure ' 'archive. Methods Mol Biol. 2017;1607:627–41.', 'journal-title': 'Methods Mol Biol'}, { 'key': '9387_CR32', 'doi-asserted-by': 'publisher', 'first-page': '349', 'DOI': '10.1016/B978-0-12-385851-1.00015-9', 'volume': '60', 'author': 'J Vallès', 'year': '2011', 'unstructured': 'Vallès J, Garcia S, Hidalgo O, Martín J, Pellicer J, Sanz M, et al. ' 'Biology, genome evolution, biotechnological issues and research ' 'including applied perspectives in Artemisia (Asteraceae). Adv Bot Res. ' '2011;60:349–419.', 'journal-title': 'Adv Bot Res'}, { 'key': '9387_CR33', 'doi-asserted-by': 'publisher', 'first-page': '101', 'DOI': '10.1089/acm.2008.0327', 'volume': '15', 'author': 'M Wilcox', 'year': '2009', 'unstructured': 'Wilcox M. Artemisia species: from traditional medicines to modern ' 'antimalarials–and back again. J Altern Complement Med (New York, NY). ' '2009;15:101.', 'journal-title': 'J Altern Complement Med (New York, NY)'}, { 'key': '9387_CR34', 'first-page': '829', 'volume': '26', 'author': 'S Jn', 'year': '2015', 'unstructured': 'Jn S, Fa KK, Aa K, Rh P, Am P, Ks L, et al. Antileishmanial activity of ' 'novel indolyl-coumarin hybrids: design, synthesis, biological ' 'evaluation, molecular docking study and in silico ADME prediction. ' 'Bioorg Med Chem Lett. 2015;26:829–35.', 'journal-title': 'Bioorg Med Chem Lett'}, { 'key': '9387_CR35', 'doi-asserted-by': 'publisher', 'first-page': '4986', 'DOI': '10.3390/ijms21144986', 'volume': '21', 'author': 'A Septembre-Malaterre', 'year': '2020', 'unstructured': 'Septembre-Malaterre A, Lalarizo Rakoto M, Marodon C, Bedoui Y, Nakab J, ' 'Simon E, et al. Artemisia annua, a traditional plant brought to light. ' 'Int J Mol Sci. 2020;21:4986.', 'journal-title': 'Int J Mol Sci'}, { 'key': '9387_CR36', 'doi-asserted-by': 'publisher', 'first-page': '353', 'DOI': '10.1186/2193-1801-2-353', 'volume': '2', 'author': 'F Ntie-Kang', 'year': '2013', 'unstructured': 'Ntie-Kang F. An in silico evaluation of the ADMET profile of the ' 'StreptomeDB database. Springerplus. 2013;2:353.', 'journal-title': 'Springerplus'}, { 'key': '9387_CR37', 'doi-asserted-by': 'publisher', 'first-page': '4066', 'DOI': '10.1021/acs.jmedchem.5b00104', 'volume': '58', 'author': 'DEV Pires', 'year': '2015', 'unstructured': 'Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule ' 'pharmacokinetic and toxicity properties using graph-based signatures. J ' 'Med Chem. 2015;58:4066–72.', 'journal-title': 'J Med Chem'}, { 'key': '9387_CR38', 'doi-asserted-by': 'publisher', 'first-page': '33', 'DOI': '10.1186/1758-2946-3-33', 'volume': '3', 'author': 'NM O’Boyle', 'year': '2011', 'unstructured': 'O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. ' 'Open babel: an open chemical toolbox. J Cheminform. 2011;3:33.', 'journal-title': 'J Cheminform'}, { 'key': '9387_CR39', 'unstructured': 'MGLTools. Get the software safely and easily. Software Informer. 2023. ' 'https://mgltools.software.informer.com/. Accessed 9 Aug 2023.'}, { 'key': '9387_CR40', 'unstructured': 'Khurshid Z. Determination of Potential Antioxidants of Artemisia annua ' 'by Computational Approaches. CUST. 2021.\xa0'}, { 'key': '9387_CR41', 'doi-asserted-by': 'publisher', 'unstructured': 'Taofeek O. Molecular Docking and Admet Analyses of Photochemicals from ' 'Nigella sativa (blackseed), Trigonella foenum-graecum (Fenugreek) and ' 'Anona muricata (Soursop) on SARS-CoV-2 Target. ScienceOpen Preprints. ' '2020. https://doi.org/10.14293/S2199-1006.1.SOR-.PPKNVFY.v1.', 'DOI': '10.14293/S2199-1006.1.SOR-.PPKNVFY.v1'}, { 'key': '9387_CR42', 'doi-asserted-by': 'publisher', 'first-page': '127', 'DOI': '10.1093/protein/8.2.127', 'volume': '8', 'author': 'AC Wallace', 'year': '1995', 'unstructured': 'Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate ' 'schematic diagrams of protein-ligand interactions. Protein Eng Des Sel. ' '1995;8:127–34.', 'journal-title': 'Protein Eng Des Sel'}, { 'key': '9387_CR43', 'unstructured': 'Biovia DS. Discovery studio visualizer. San Diego, CA, USA. 2017. ' 'Available at https://www.3ds.com/products/biovia/discovery-studio. ' 'Accessed 05 Aug 2023.'}, { 'key': '9387_CR44', 'doi-asserted-by': 'publisher', 'first-page': '603037', 'DOI': '10.3389/fmolb.2020.603037', 'volume': '7', 'author': 'AAA Abdusalam', 'year': '2020', 'unstructured': 'Abdusalam AAA, Murugaiyah V. Identification of potential inhibitors of ' '3CL protease of SARS-CoV-2 from ZINC database by molecular docking-based ' 'virtual screening. Front Mol Biosci. 2020;7:603037.', 'journal-title': 'Front Mol Biosci'}, { 'key': '9387_CR45', 'doi-asserted-by': 'publisher', 'first-page': '18', 'DOI': '10.1016/j.sjbs.2021.10.060', 'volume': '29', 'author': 'M Vijayakumar', 'year': '2022', 'unstructured': 'Vijayakumar M, Janani B, Kannappan P, Renganathan S, Al-Ghamdi S, ' 'Alsaidan M, et al. In silico identification of potential inhibitors ' 'against main protease of SARS-CoV-2 6LU7 from Andrographis panniculata ' 'via molecular docking, binding energy calculations and molecular ' 'dynamics simulation studies. Saudi J Biol Sci. 2022;29:18–29.', 'journal-title': 'Saudi J Biol Sci'}, { 'key': '9387_CR46', 'doi-asserted-by': 'publisher', 'first-page': '57', 'DOI': '10.1007/s42250-021-00296-y', 'volume': '5', 'author': 'GM Benhander', 'year': '2022', 'unstructured': 'Benhander GM, Abdusalam AAA. Identification of potential inhibitors of ' 'SARS-CoV-2 main protease from Allium roseum L. Molecular docking study. ' 'Chem Afr. 2022;5:57–67.', 'journal-title': 'Chem Afr'}, { 'key': '9387_CR47', 'doi-asserted-by': 'publisher', 'first-page': '6679', 'DOI': '10.1073/pnas.0408930102', 'volume': '102', 'author': 'M Karplus', 'year': '2005', 'unstructured': 'Karplus M, Kuriyan J. Molecular dynamics and protein function. Proc Natl ' 'Acad Sci USA. 2005;102:6679–85.', 'journal-title': 'Proc Natl Acad Sci USA'}, { 'key': '9387_CR48', 'doi-asserted-by': 'publisher', 'first-page': '313', 'DOI': '10.1016/j.jpha.2020.03.009', 'volume': '10', 'author': 'M Tahir Ul Qamar', 'year': '2020', 'unstructured': 'Tahir Ul Qamar M, Alqahtani SM, Alamri MA, Chen L-L. Structural basis of ' 'SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal ' 'plants. J Pharm Anal. 2020;10:313–9.', 'journal-title': 'J Pharm Anal'}, { 'key': '9387_CR49', 'doi-asserted-by': 'publisher', 'first-page': '1763', 'DOI': '10.1126/science.1085658', 'volume': '300', 'author': 'K Anand', 'year': '2003', 'unstructured': 'Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus ' 'main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. ' 'Science. 2003;300:1763–7.', 'journal-title': 'Science'}, { 'key': '9387_CR50', 'doi-asserted-by': 'publisher', 'first-page': '91', 'DOI': '10.1007/s12551-016-0247-1', 'volume': '9', 'author': 'NS Pagadala', 'year': '2017', 'unstructured': 'Pagadala NS, Syed K, Tuszynski J. Software for molecular docking: a ' 'review. Biophys Rev. 2017;9:91–102.', 'journal-title': 'Biophys Rev'}, { 'key': '9387_CR51', 'doi-asserted-by': 'publisher', 'first-page': '581', 'DOI': '10.1002/jmr.2471', 'volume': '28', 'author': 'E Yuriev', 'year': '2015', 'unstructured': 'Yuriev E, Holien J, Ramsland PA. Improvements, trends, and new ideas in ' 'molecular docking: 2012–2013 in review. J Mol Recognit. 2015;28:581–604.', 'journal-title': 'J Mol Recognit'}, { 'key': '9387_CR52', 'doi-asserted-by': 'publisher', 'first-page': '1273', 'DOI': '10.2174/15680266113139990033', 'volume': '13', 'author': 'F Cheng', 'year': '2013', 'unstructured': 'Cheng F, Li W, Liu G, Tang Y. In silico ADMET prediction: recent ' 'advances, current challenges and future trends. Curr Top Med Chem. ' '2013;13:1273–89.', 'journal-title': 'Curr Top Med Chem'}], 'container-title': 'BMC Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12879-024-09387-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s12879-024-09387-w/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12879-024-09387-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 5, 15]], 'date-time': '2024-05-15T11:03:32Z', 'timestamp': 1715771012000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09387-w'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 5, 15]]}, 'references-count': 52, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2024, 12]]}}, 'alternative-id': ['9387'], 'URL': 'http://dx.doi.org/10.1186/s12879-024-09387-w', 'relation': {}, 'ISSN': ['1471-2334'], 'subject': [], 'container-title-short': 'BMC Infect Dis', 'published': {'date-parts': [[2024, 5, 15]]}, 'assertion': [ { 'value': '14 February 2024', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '8 May 2024', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '15 May 2024', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'It’s a computational work, ethical approval not required.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics approval and consent to participate'}}, { 'value': 'Not applicable.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent for publication'}}, { 'value': 'The authors declare no competing interests.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '495'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit